The phase 3 results, presented at the American Academy of Dermatology Annual Meeting over the weekend, matched previous data from a previous late-stage study of the IL-13-targeting monoclonal antibody, Lilly said in a Sunday press release. The company evaluated 50 patients with moderate to severe atopic dermatitis and darker skin tones in the ADmirable trial over 16 weeks. The trial makeup included 80% people who self-identify as Black or African American, 14% as Asian and 6% as American Indian or Alaska Native. Of the 50 patients, 11 also self-identified as Hispanic/Latinx.
Almirall`s Ebglyss (Lebrikizumab) Receives Approval in Europe
Almirall Receives European Commission Approval of EBGLYSS
INDIANAPOLIS, Oct. 20, 2023 /PRNewswire/ -- Patients with moderate-to-severe atopic dermatitis who continued treatment with investigational lebrikizumab for up to two years experienced sustained skin clearance, itch relief and reduced disease severity with monthly maintenance dosing as demonstrated in the ADjoin long-term extension study from Eli Lilly and Company (NYSE: LLY). Results from ADjoin will be presented at the 43rd Annual Fall Clinical Dermatology Conference happening from October 19-22 in Las Vegas, Nevada.1
Almirall: Nearly 80% of patients with moderate-to-severe atopic dermatitis maintained clear or almost-clear skin with lebrikizumab monthly maintenance dosing at two years
Almirall's Lebrikizumab Improves Signs and Symptoms of Moderate-to-Severe Atopic Dermatitis (AD) in Patients Inadequately Controlled With or Ineligible for Cyclosporine1
The FDA has rejected Lilly’s investigational atopic dermatitis treatment lebrikizumab over findings uncovered during an inspection of a third-party contract manufacturing organization, Lilly said Monday.
EBGLYSS® (lebrikizumab) Receives Positive CHMP Opinion for Moderate-to-severe Atopic Dermatitis
INDIANAPOLIS, May 1, 2023 /PRNewswire/ -- New secondary analysis from Eli Lilly and Company's (NYSE: LLY) Phase 3 clinical development program showed patients receiving lebrikizumab who were assessed at 16 weeks experienced improved or cleared face or hand dermatitis, which can be particularly burdensome and stigmatizing because these areas are highly visible parts of the body. An additional secondary analysis further demonstrated lebrikizumab's stable and long-lasting results at one year of treatment in patients with moderate-to-severe atopic dermatitis (AD), commonly called eczema. These results from the ADvocate and ADhere studies were presented at the 5th annual Revolutionizing Atopic Dermatitis (RAD) Congress.
Almirall: The New England Journal of Medicine (NEJM) and the British Journal of Dermatology (BJD) Publish Ph3 Data Evaluating lebrikizumab Efficacy and Safety in Moderate-to-Severe Atopic Dermatitis